News | March 26, 2015

Edwards' CEO Addresses Senate Committee on Preserving, Strengthening U.S. Medical Device Innovation

Comments highlight improved collaboration, need to reduce regulatory and financial barriers

March 26, 2015 — Edwards Lifesciences Corp. announced that chairman and CEO Michael A. Mussallem served as an invited expert panelist on behalf of the Advanced Medical Technology Association (AdvaMed) at the United States Senate Health, Education, Labor and Pensions Committee hearing on "Continuing America's Leadership: Advancing Research and Development for Patients."

"As medical technology innovators, it's our passion and mission to continue developing better solutions to improve the lives of patients," said Mussallem.  "To maximize the impact of this work, it is imperative that we forge a path toward revitalizing the medical technology ecosystem in the United States. Continued innovation is vital to improving clinical outcomes, enhancing patients' quality of life and bringing increased value to the healthcare system."

Mussallem noted collaborative engagement and significant progress by the U.S. Food & Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) in better understanding and improving the predictability and approval timelines for future generations of medical devices.

He also addressed opportunities to further reduce barriers in regulatory approval and reimbursement, in order to help promote America's continued worldwide leadership in medical device development and also to support innovation. His comments focused on three primary areas:

  • the acceleration of FDA's vision to improve the regulatory process;
  • the need to strengthen the research and development infrastructure so it is second to none; and
  • continued encouragement of innovation by addressing issues throughout the entire ecosystem.

 

Mussallem also drew upon Edwards' experience with the Sapien transcatheter aortic heart valves to discuss the current regulatory environment in the United States.

For more information: www.edwards.com


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
Subscribe Now